Elevation Oncology, Inc.
(ELEV)
Add Watchlist
3.70 USD -0.01
Closed: 03 May, 3:55 pm
Symbol ELEV
Market Cap 180M
Price 3.70
Open 3.81
52-wk High 5.89
50 Day Avg 4.31
Earnings Announcement 2024-05-20
Website https://elevationoncology.com
Name Elevation Oncology, Inc.
Shares Outstanding 48,651,100
Change % -3.1414%
Low 3.69
52-wk Low 0.36
200 Day Avg 1.91
Last Dividend 0.00
Exchange NASDAQ
Volume 431,645
Previous Close 3.82
High 4.13
EPS -1.34
PE -2.76
Avg Volume 1,032,803
CUSIP 28623U101
Elevation Oncology, Inc. Outlook
Description Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Currency USD
ISIN US28623U1016
Industry Biotechnology
Changes -0.12
CUSIP 28623U101
Range 0.36 - 5.89
Beta 1.36
CIK 0001783032

Elevation Oncology, Inc. News

08-Mar-2024 8:02 PM

All Three of Our Analysts Agree

Personalized health screening from a “smart toilet”

05-Mar-2024 6:00 PM

Trim the Fat: 3 Overbought Stocks Poised for a Pullback

Recently, I watched portions of a YouTube video that tangentially but importantly related to overbought stocks to sell. An options trader boasted about an 80% success rate with his system, which sounded like nonsense.

05-Mar-2024 4:50 PM

Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024

-- Data support ongoing development of antibody-drug conjugate (ADC) program targeting HER3-expressing cancers – -- On-track to nominate development candidate in 2024 -- BOSTON , March 5, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical need, today announced that it will present preclinical proof-of-concept data for its differentiated HER3-targeting antibody-drug conjugate (ADC) program in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California. "We are excited to share preclinical proof-of-concept data for our HER3-ADC program.

28-Feb-2024 7:30 AM

Elevation Oncology to Participate in Upcoming Investor Conferences

BOSTON , Feb. 28, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that members of management will participate in upcoming investor conferences in March: TD Cowen 44th Annual Health Care Conference. Fireside chat on Wednesday, March 6, 2024 at 10:30 AM ET in Boston, MA.

23-Feb-2024 9:17 AM

3 Stock Winners That Are Up 400% or More in 2024

The stock market has seen a remarkable surge in recent months, climbing 21% since the end of October. Rallies as strong as this one tend to yield several stock winners, which in this case are primarily GenAI-focused companies.

05-Sep-2023 7:30 AM

Elevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

NEW YORK , Sept. 5, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph Ferra, Chief Executive Officer of Elevation Oncology, will present at the H.C.

09-Jun-2023 8:48 AM

Why Is Elevation Oncology (ELEV) Stock Down 26% Today?

Elevation Oncology (NASDAQ: ELEV ) stock is taking a beating on Friday after the healthcare company announced a public stock offering. That public offering of ELEV stock has the company selling 17,810,000 shares at a price of $2.25 each.

30-May-2023 6:56 AM

Steve Cohen's Point72 Disclosed 8.7% Stake In Elevation Oncology

Elevation Oncology NASDAQ: ELEV is a biotech company that focuses on discovering and developing cancer therapies. The company aims to treat patients with various solid tumors with significant unmet medical needs.

26-May-2023 10:06 AM

Why Is Elevation Oncology (ELEV) Stock Up 57% Today?

Elevation Oncology (NASDAQ: ELEV ) stock is on the rise Friday despite a lack of news from the pharmaceutical company. There's no news that explains why shares of ELEV stock are taking off today.

25-May-2023 6:21 PM

5 Penny Stocks To Watch Before Next Week; Time To Buy?

If you're like many retail traders in the stock market today, penny stocks are a popular prospect. This article looks at some of the most active penny stocks today with late-breaking momentum.

23-Mar-2023 11:28 AM

Are Medical Stocks Lagging Elevation Oncology (ELEV) This Year?

Here is how Elevation Oncology, Inc. (ELEV) and Senesco Technologies Inc. (ELOX) have performed compared to their sector so far this year.